Pfenex, HHS Begin Clinical Studies for New Anthrax Vaccine; Robin Robinson Comments
Pfenex Inc. and the Department of Health and Human Services have begun  clinical research for a new anthrax vaccine under a 30-month, $15.9 million contract. The Biomedical Advanced Research and Development Authority will lead the project to develop the experimental vaccines Px563L and RPA563, which target the anthrax cell-binding protein, HHS said Monday. “It is paramount to […] More